Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012 - New Market Report

Sept. 22, 2012 - PRLog -- Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) therapeutic pipeline. This report provides information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris). 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/463774_plaque_psoriasis_psoriasis_vulgaris_pipeline.aspx
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Plaque Psoriasis (Psoriasis Vulgaris).
* A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Plaque Psoriasis (Psoriasis Vulgaris) therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Plaque Psoriasis (Psoriasis Vulgaris) Therapeutic Products under Development, Key Players in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Overview, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline, Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Plaque Psoriasis (Psoriasis Vulgaris) Overview
Therapeutics Development
An Overview of Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris)
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics under Development by Companies
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Products under Development by Companies
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Development
Alcon, Inc.
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
LEO Pharma A/S
Celgene Corporation
Protalix BioTherapeutics, Inc.
Provectus Pharmaceuticals, Inc.
R-Tech Ueno, Ltd.
Deltanoid Pharmaceuticals Inc.
CREABILIS Therapeutics S.r.l.
Anacor Pharmaceuticals, Inc.
Therapeutics Incorporated
Vascular Biogenics Ltd.
Avesthagen Limited
Maruho Co.,Ltd.
Centocor Ortho Biotech, Inc.
XBiotech USA, Inc.
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 827 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASKP1240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-10004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIN457 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT327 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stelara - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEO 90100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEO 22811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT637 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AN2728 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNTO 1959 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTU-1096 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
9-Cis-Beta-Carotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M518101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Halobetasol Proprionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COL121 - Drug Profile
Product Description

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4637...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.